Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Co-Diagnostics, Inc. (CODX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $622,489 | $3.9M | $6.8M | $34.2M | $97.9M | $74.6M | $214,974 | $39,911 | $7,662 | — |
| Gross profit | $400,112 | $2.9M | $2.6M | $28.7M | $86.3M | $58.0M | $102,543 | $30,520 | $7,360 | — |
| Research & development | $19.1M | $21.0M | $23.0M | $17.4M | $15.0M | $3.2M | $1.4M | $1.4M | $1.0M | $731,474 |
| Operating expenses | $50.6M | $43.0M | $45.3M | $55.7M | $40.2M | $16.3M | $6.0M | $6.1M | $4.6M | $1.7M |
| Operating income | −$50.2M | −$40.1M | −$42.7M | −$27.0M | $46.1M | $41.7M | −$5.9M | −$6.1M | −$4.6M | −$1.7M |
| EBITDAderived | −$49.1M | −$38.7M | −$41.5M | −$25.7M | $46.4M | $41.8M | −$5.8M | −$6.1M | −$4.5M | −$1.7M |
| Net income | −$46.9M | −$37.6M | −$35.3M | −$14.2M | $36.7M | $42.5M | −$6.2M | −$6.3M | −$7.0M | −$1.9M |
| Basic EPSper diluted share | -$35.25 | -$37.22 | -$1.20 | -$0.45 | $1.27 | $1.59 | -$0.37 | -$0.50 | -$0.63 | — |
| Diluted EPSper diluted share | -$35.25 | -$37.22 | -$1.20 | -$0.45 | $1.23 | $1.52 | -$0.37 | -$0.50 | -$0.63 | — |